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Abstract
Background: Concomitant with the development of in vitro diagnostic multivariate index assays (IVDMIAs) to
improve the diagnostic efficiency of ovarian cancer detection is the need to identify appropriate biostatistical
approaches to assess improvements in risk predication. In this study, we assessed the utility of three different
approaches for comparing diagnostic efficiency of an ovarian cancer multivariate assay in a retrospective case -
control phase 2 biomarker trial. The control cohort included both disease-free women and women with benign
gynecological conditions to more accurately reflect the target population of symptomatic women.
Methods: The study cohort comprised plasma samples from 244 healthy controls, 223 women with benign
gynecological conditions, 53 borderline ovarian cancer cases and 222 women with malignant epithelial ovarian
cancer. A multivariate classification model was developed that incorporated plasma concentrations of CA125, C-
reactive protein (CRP), serum amyloid-A (SAA), interleukin-6 (IL6) and interleukin-8 (IL8) that were measured using
in vitro diagnostics assays on medical device approved clinical analysers. The posterior probability values derived
from the implemented algorithm were used for comparisons of the diagnostic performance between the
multianalyte panel and CA125 using multiple methods; area under the curve (AUC) of the receiver operating
characteristics curve, integrated discrimination improvement (IDI) and net reclassification improvement (NRI).
Results: Each of the biomarkers displayed significantly elevated plasma concentrations in malignant ovarian cancer
patients compared with either benign or control subjects. For the discrimination of borderline and malignant
ovarian cancer from control and benign subjects, the multivariate classification model showed a significantly
greater AUC than that for CA125 alone (88.4% versus 84.3%, respectively, p < 0.001). At a posterior probability
threshold of 0.5, the IVDMIA delivered a specificity of 92.3% and a sensitivity of 76.4%. When set at a specificity of
95%, the multimarker diagnostic delivered a sensitivity of 69.5% compared with 62.5% for CA125. Enhanced
diagnostic performance of the IVDMIA over the use of CA125 alone was confirmed statistically by alternative
comparisons using IDI and NRI.
Conclusions: This study confirms in an independent sample set that a blood-based multianalyte assay has
significant advantages over CA125 for distinguishing symptomatic women with borderline and malignant ovarian
cancer from controls or those with benign disease.
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Estimates by the International Agency for Research on
Cancer indicate that the number of new cases of ovarian
cancer for the year 2008 would reach 225,000 with
140,000 expected deaths from this disease in the same
period [1]. In the USA, it is estimated that ovarian can-
cer will account for 13,850 deaths in 2010, making it the
fifth most lethal malignancy in females [2]. Of particular
significance is the fact that the distribution of ovarian
cancers by stage at the time of diagnosis is dramatically
skewed towards late stage disease, with only approxi-
mately 30% of ovarian cancers diagnosed when tumours
represent localised or regionally contained disease [2].
Overall, five-year survival rate for patients in the USA
diagnosed across all stages of ovarian cancer is 46% [2].
Five-year survival rates among patients diagnosed with
localised disease, however, are around 94%, but fall to
73% in patients diagnosed with regional malignancy and
are only 28% in patients diagnosed with late stage dis-
ease [2]. These data are consistent with the proposal
that patients diagnosed with early stage ovarian malig-
nancies have a distinct survival advantage and raise the
possibility that improved methods to detect more early
stage ovarian malignancies may provide improved clini-
cal outcomes.
Due to low incidence of ovarian cancer in most devel-
oped populations (1 per 2,500 women per year), it has
been suggested that for an acceptable ovarian cancer
screening test to be implemented, it would need to per-
form with a minimum specificity of 99.6% to achieve a
positive predictive value of 10% for screening the gen-
eral population of post-menopausal women [3]. At pre-
sent, no screening method has been demonstrated to be
sufficiently robust to allow for population based screen-
ing for ovarian cancer.
CA125, a high molecular weight glycoprotein remains
the most widely used biomarker for confirmation of
diagnosis and management of ovarian cancer. Although
it is commonly used as an aid in the diagnosis of ovar-
ian malignancy, it has significant limitations in terms of
sensitivity and specificity. A review of pre-operative
serum CA125 concentrations in ovarian cancer patients
by FIGO stage and by histological type showed that
CA125 was elevated in only 50% of stage I ovarian can-
cer cases and in 69% of mucinous ovarian tumours
while being far more prominently expressed in patients
with late stage serous tumours [4]. Elevation of circulat-
ing CA125 concentrations have also been documented
in benign gynecological conditions, pregnancy and other
malignancies, making CA125 less useful as a selective
biomarker for the detection of ovarian cancer [4].
Some improvement in the preoperative diagnosis of
ovarian cancer has been achieved by combining serum
CA125 concentration, ultrasound score and menopausal
status into a risk of malignancy index (RMI) which was
shown to outperform the use of CA125 alone to discri-
minate between a benign and malignant pelvic mass [5].
Furthermore, since as many as 20% of ovarian cancers
express little or no CA125, it is likely that additional
secreted biomarkers may be able to complement the use
of CA125 to improve diagnostic efficiency [6]. Different
approaches have been taken to test the use of various
multimarker panels that include CA125 to generate a
multivariate model to predict the likelihood of ovarian
cancer in various patient cohorts. Combinations of bio-
markers and multivariate analyses have demonstrated
increases in diagnostic efficiency for predicting ovarian
malignancy in comparison to using CA125 alone [7-13].
Several of these multimarker tests are aimed at more
accurately distinguishing between malignant and benign
adnexal masses, thus allowing for more streamlined
triage of these patients [10,11,14].
Previously, we reported the results of a retrospective
case-control study that assessed the performance of a
f i v eb i o m a r k e rp a n e l( C A 1 2 5 ,C R P ,S A A ,I L 6a n dI L 8 )
and demonstrated increased diagnostic efficiency of this
panel over CA125 alone as assessed by the area under
the receiver operating characteristic curve (AUC) using
a bootstrapping procedure [8]. This initial multianalyte
approach was limited to a comparison of normal healthy
controls with confirmed cases of malignant ovarian can-
cer and demonstrated significant diagnostic advantage
over CA125 for detection of both early and late stage
ovarian malignancy.
A recent trend in the development of more efficient
diagnostic tests has been the use of algorithm-base mul-
tivariate index assays. With the development of this new
class of diagnostic, the discipline has sought new biosta-
tistical approaches for assessing and quantifying incre-
mental gains in diagnostic efficiency. Traditionally, the
AUC has been used as a measure and comparator of
diagnostic efficiency. Several investigators have argued
that this measure alone may be imperfect and inefficient
for comparing the true clinical usefulness of alternative
marker panels [15,16]. It was observed that when evalu-
ating improvement in risk assignment of biomarkers,
very large odds ratios were often associated with very
small increases in the AUC. This feature of the receiver
operator characteristic curve analysis limits its utility in
identifying putative beneficial contributions of new bio-
markers to algorithm-based models. As a result, alterna-
tive methods for comparison of diagnostic efficiency
have been developed and successfully applied including
integrated discrimination improvement (IDI) that
assesses improvement in risk discrimination based on
the integral of sensitivity and specificity of all possible
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oped for the derivation of prognostic indicators from
prospective cohort studies, but have been applied in the
context of developing diagnostic indicators from case-
control studies [17-19].
To further validate the efficacy of the previously
described multianalyte panel and to test the utility of
different approaches for assessing diagnostic efficiency,
we have evaluated the performance of the IVDMIA on
an independent cohort of 742 patient samples that
included a significant proportion of benign gynecological
pathologies that more accurately defines the target
population. The performance of the IVDMIA was com-
pared to CA125 alone using AUC bootstrapping
approaches as well as IDI and NRI in order to deter-
mine the benefit of the multimarker model in correctly
classifying women who present clinically with symptoms
of ovarian cancer.
Methods
Study samples
The study population comprised 244 apparently healthy
normal women, 223 patients with benign gynecological
conditions, 53 patients with borderline ovarian tumours
and 222 patients with malignant ovarian tumours (Table
1).
All patients underwent surgical removal of ovarian
mass or cysts and pathology examination of tissue sec-
tions was used to provide a definitive diagnosis. Patients
classified as malignant were women with histologically
confirmed epithelial ovarian cancer patients and patients
classified as benign consisted of women diagnosed with
a range of common benign gynecological conditions
including serous and mucinous cystadenoma, cystadeno-
fibromas, endometriotic cysts, follicular cysts, fibrothe-
coma and endometriosis.
Plasma samples were collected with consent from
healthy women or from patients prior to surgery or
treatment and no special conditions were implemented
in preparation for blood collection. The overall protocol
was approved by the Mercy Hospital for Women
Human Research and Ethics Committee (R09/06). The
majority of the samples were provided from banked
sample collections at the National University of Singa-
pore, Victorian Cancer Biobank and the West Australian
Research and Tissue Network from which part of the
samples were collected via the Australian Ovarian Can-
cer Study. Samples obtained from normal apparently
healthy women were collected with consent by ARL
pathology as part of the study design. A further 234
samples were collected from gynecological oncology
patients attending specialist clinics at the Mater Hospi-
tal, Brisbane, Australia and the Women’s Clinic, South-
end University Hospital, Essex, UK under local ethics
approvals. Blood samples were collected into EDTA
vacutainer tubes and samples stored as 250-1000 μLa l i -
quots at -80°C until required for analysis. Samples were
thawed once, dispensed into single use assay aliquots
and were re-labelled to create a totally blind set for bio-
marker analysis. The order of assay for each blinded
sample was further randomised to remove any possible
assay bias.
Study design
The present study was a case-control retrospective trial
design to test the efficacy of a biomarker panel to detect
ovarian cancer in symptomatic women, similar to that
previously described [8]. The study cohort included
both confirmed cases of malignant epithelial ovarian
c a n c e r ,b o r d e r l i n eo v a r i a nt u m o u r sa sw e l la sc o n t r o l
patients with benign gynecological pathologies. A group
of apparently healthy age-matched normal women have
been included as part of the control cohort.
Biomarker quantitation
Five biomarkers, CA125, CRP, SAA, IL6 and IL8, pre-
viously associated with ovarian cancer [8] were analysed
in each sample using the clinical pathology platforms
Immulite and BN-II (Siemens Healthcare Diagnostics).
CA125 (Siemens OM-MA assay), IL6 and IL8 were ana-
lysed on the Immulite while CRP and SAA were ana-
lysed on the BN-II platform. Analytes were analysed
sequentially on each instrument from a single sample
aliquot to avoid multiple freeze-thaw cycles and sample
variation. All assays were performed as per the manufac-
turer’s instructions. QC measurements were within the
expected ranges and coefficients of variation for the
Table 1 Characteristics of the study population
No. of
samples
Stage Age (years)
I II III IV UNK Range Median Mean
(SD)
Normal 244 19-85 50 51
(13)
Benign 223 20-90 47 49
(15)
Borderline 53 19-79 47 48
(14)
Malignant 222 22-88 58 58
(14)
Ser 130 14 14 80 12 10
Endo 19 7 6 4 - 2
Muc 16 8 0 3 - 5
CC 16 8 1 7 - -
Other 41 5 6 12 2 16
Staging data were unavailable for a proportion of the diagnosed malignant
cases (UNK).
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and IL8) and 8.2% (SAA). The limit of analytical sensi-
tivity as specified by the manufacturer was 1 U/mL
(CA125), 0.15 mg/L (CRP), 0.80 mg/L (SAA), 1 pg/mL
(IL6) and 2.5 pg/mL (IL8). In the event that sample
determinations delivered values at the limit of analytical
sensitivity of the assay, values were entered for analysis
as limit of sensitivity/2 so that a definitive lower value
could be used in statistical analyses.
Statistical analysis
Statistical comparison of multiple groups was assessed
using the Kruskal-Wallis test and Dunn’s multiple com-
parison was employed as a post-hoc test to determine
differences between groups. For two sample group com-
parisons, statistical significance was determined using
the Mann Whitney test (GraphPad Prism, La Jolla, CA,
USA). Comparison of patient age across the groups was
performed using one-way ANOVA followed by Tukey’s
multiple comparison test. In all cases, a p value < 0.05
was considered to be statistically significant.
Multivariate modelling
Multivariate model development and statistical compari-
sons of biomarker models were performed by an inde-
pendent biostatistician (Emphron Informatics Pty Ltd,
Toowong, Qld, Australia). A multivariate classification
model that incorporated all five biomarkers was devel-
oped using a stochastic gradient boosting model with a
logistic loss function as previously described [8]. The
implemented classification algorithm reported a poster-
ior probability value (i.e. the likelihood that a sample
came from a woman with ovarian cancer) for each
patient sample using Leave-One-Out-Cross Validation
[20]. The cross-validated predicted probabilities were
used to generate the ROC curve for the IVDMIA. Com-
parisons between the diagnostic efficiency of CA125
alone and the IVDMIA were first tested by assessing
AUC as calculated using the Wilcoxon statistic [21]. As
the AUC for CA125 and for the biomarker panel are
not statistically independent, since they are based on the
same patients, the difference in AUC between the diag-
nostics were statistically assessed using a bootstrap pro-
cedure [22]. The number of bootstrap samples used in
this analysis was n = 10,000, the estimators considered
were the AUC as well as the difference between the
AUC’s, and the measures of accuracy were the 95% con-
fidence intervals.
Statistical differences in diagnostic efficiency between
CA125 and the IVDMIA were further assessed using:
IDI that is based on a measure of separation in pre-
dicted probabilities for case and control groups; and
NRI that assesses reclassification tables and quantifies
the correct movement in categories [15,16]. Although
originally developed in the context of assessing the con-
tribution of additional markers to prognostic indicators
using prospective cohort studies, these techniques have
been adapted for retrospective case control studies
[17-19].
Results
Characteristics of the study population
The age range for the normal control, benign, borderline
and malignant ovarian cancer groups was similar (Table
1), however, the mean age of the malignant ovarian can-
cer group was significantly higher compared with the
other groups (51 vs 49 vs 48 vs 58 respectively, p <
0.001). The control, non-malignant cohort was made up
of 244 (52.2%) normal control women and 223 (47.8%)
patients with benign gynecological lesions with a mean
age of 50 ± 14 (SD). The malignant ovarian cancer
cohort comprised 130 (58.5%) serous, 19 (8.6%) endo-
metrioid, 16 (7.2%) mucinous, 16 (7.2%) clear cell and
41 (18.5%) of other types that included predominantly
mixed forms and adenocarcinomas with no specific his-
totype recorded (Table 1). A total of 33 (14.9%) of
malignant ovarian cancer samples had no staging data
reported, 42 (18.9%) were diagnosed with Stage I dis-
ease, 27 (12.2%) with Stage II, 106 (47.7%) Stage III and
14 (6.3%) with Stage IV disease (Table 1).
Plasma biomarker concentrations in control, benign,
borderline and malignant ovarian cancer patients
The distribution of plasma concentrations of each
tumour marker in individual patient samples is shown
in Figure 1. Circulating concentrations of all measured
biomarkers showed a significant difference (p < 0.05)
between normal control samples and patients with
malignant disease. Each biomarker also demonstrated a
significant difference in plasma concentrations between
benign and malignant tumour groups (p < 0.05), indicat-
ing that these analytes could discriminate between either
normal controls or benign cases and those with malig-
nant epithelial ovarian carcinoma. Concentrations of
CRP, SAA and IL6 were indistinguishable between nor-
mal controls and patients with benign conditions.
Patients with borderline ovarian tumours displayed sig-
nificantly elevated concentrations of CA125 compared
with either normal controls or benign patients, while
IL6 and IL8 concentrations were slightly elevated in bor-
derline patients compared with normal controls (Figure
1 and Table 2).
The median plasma concentration of all biomarkers
tested was significantly elevated (p < 0.05) in patients
diagnosed with malignant serous ovarian carcinoma as
well as ovarian carcinomas of non-serous histotypes
compared with either normal controls or patients with
benign conditions (Figure 2). Only circulating
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< 0.05) between patients with serous ovarian cancer
compared with patients with non-serous tumours, with
median CA125 concentrations of serous patients being
approximately three-times higher than those in non-ser-
ous patients (Figure 2). No significant difference was
found in concentrations of CRP, SAA, IL6 or IL8
between serous and non-serous ovarian cancer patients
Figure 1 Comparison of individual patient plasma biomarker concentrations across all patient groups. A total of 244 normal controls
(Con), 223 patients with benign gynecological conditions (Ben), 53 patients with borderline ovarian tumours (B/L) and 222 cases of malignant
epithelial ovarian cancer (Malignant) were analysed. Open circles indicate the individual values of each patient measurement shown on a log
scale and horizontal lines show median concentration of each group. *: p < 0.05, compared with Con group; ^: p < 0.05 compared with Ben
group (Kruskal-Wallis test followed by Dunn’s multiple comparison test)
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kers could more effectively discriminate non-serous
ovarian cancer cases from control and/or benign
patients.
Further analysis demonstrated that each of the bio-
markers tested could significantly discriminate between
normal controls and either early (Stages I-II) or late
(Stages III-IV) stage ovarian cancer patients (Table 2).
Similarly, all plasma biomarkers measured were signifi-
cantly higher in early stage ovarian cancer patients com-
pared with those with benign conditions (Table 2). Only
IL6 and IL8 demonstrated a significant elevation in
plasma concentration between borderline tumours and
early stage (Stage I-II).
Multivariate modelling and comparisons of diagnostic
performance
We first compared AUC-ROC of CA125 with that of
the multimarker panel modelled using only normal con-
trols (n = 244) and malignant ovarian cancer patients (n
= 222). The AUC of the IVDMIA was significantly
greater than that of CA125 alone (94.9 vs 91.9, p =
0.007).
Comparisons of AUC of CA125 with the IVDMIA for
discrimination of control/benign from borderline and
malignant epithelial ovarian cancer patients are shown
in Table 3. Sensitivities are reported at the defined spe-
cificities of 90% and 95%. The use of CA125 as a single
biomarker delivered an AUC of 84.3% with a sensitivity
of 62.5% at either a specificity of 90% or 95%. The IVD-
MIA delivered an AUC of 88.4% with a sensitivity of
77.5% at 90% specificity and a sensitivity of 69.5% at a
defined specificity of 95%. The AUC was significantly
different (p < 0.001) between CA125 and IVDMIA
(Table 4) and the sensitivity of the IVDMIA was 15%
higher at 90% specificity and 7% higher than for CA125
at 95% specificity.
The relationship between predicted posterior probabil-
ity values for individual patient samples across all
groups and within the combined control + benign ver-
sus borderline + malignant ovarian cancer groups is
shown in Figure 3 and shows an incremental increase in
posterior probability values across benign, borderline
and malignant ovarian tumor patients. The algorithm
derived posterior probability values for the discrimina-
tion of control/benign from borderline/malignant
epithelial ovarian cancer patients was shown to be sig-
nificantly different (p < 0.0001).
The predictive ability of the IVDMIA was further
compared with that of CA125 using additional two sta-
tistical approaches (Table 4). Both the bootstrapped IDI
comparison (p < 0.001) and NRI analysis (p < 0.001)
demonstrated that the diagnostic performance of the
IVDMIA was significantly enhanced in comparison to
the use of CA125 alone for the discrimination of bor-
derline and malignant ovarian cancer patients from the
control/benign group.
Based on using a posterior probability threshold of
0.5, the multianalyte panel delivered a specificity of
92.3% and a sensitivity of 76.4%. Using this defined
threshold of 0.5 for discrimination of borderline and
malignant cases from the control/benign group, the
multimarker algorithm correctly predicted 97.9% of
normal controls, 86.1% of patients with benign lesions,
Table 2 Plasma biomarker concentrations
Biomarker Normal Control (n
= 244)
Benign
(n = 223)
Borderline
(n = 53)
Early Stage Malignant (Stages I &
II) (n = 69)
Late Stage Malignant
(Stages III & IV)
(n = 120)
CA-125 Mean ± SE 6.05 ± 10.4 27.35 ± 10.2 180.3 ± 137 380.9 ± 97 1337.0 ± 420
(U/mL) Median
(range)
4.10 (0.5-146)
a 7.60 (0.5-
2219)
a
13.1 (1.2-
7266)
a, b
52.3 (0.5-4277)
a, b 208.5 (3.3-47206)
a, b
CRP Mean ± SE 3.99 ± 0.7 8.20 ± 1.5 10.05 ± 3.6 16.73 ± 3.4 39.65 ± 4.5
(mg/L) Median
(range)
1.38 (0.08-149.4) 1.81 (0.08-
172.7)
3.09 (0.17-
186.7)
4.77 (0.10-139.1)
a, b 21.80 (0.30-309.5)
a, b
SAA Mean ± SE 10.82 ± 2.5 29.00 ± 7.9 22.11 ± 11.3 47.47 ± 13.3 127.7 ± 24.3
(mg/L) Median
(range)
4.34 (0.77-489.0) 4.95 (0.80-
1337)
4.74 (1.20-
593.2)
8.50 (1.00-737.0)
a, b 24.23 (0.96-1958)
a, b
IL-6 Mean ± SE 2.11 ± 0.23 2.61 ± 0.25 6.26 ± 2.79 8.54 ± 1.71 20.09 ± 6.29
(pg/ml) Median
(range)
1.00 (1.00-38.50) 1.00 (1.00-
29.50)
1.00 (1.00-
146.0)
4.10 (1.00-93.70)
a, b 8.45 (1.00-628.0)
a, b
IL-8 Mean ± SE 3.73 ± 0.33 10.27 ± 1.81 16.83 ± 5.67 19.27 ± 4.88 29.36 ± 5.88
(pg/mL) Median
(range)
2.50 (2.50-58.70) 2.50 (2.50-
292.0)
a
2.50 (2.50-
183.0)
a
2.50 (2.50-239.0)
a, b 6.10 (2.50-408.0)
a, b
Data are presented as mean ± SE and median (range).
a: p < 0.05 compared with normal controls and
b: p < 0.05 compared with benign group (Kruskal-Wallis
followed by Dunn’s Multiple Comparison test). Note that 33 malignant ovarian cancer samples were excluded from early/late stage analysis since stage data was
not recorded.
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ian cancers of all stages. Of the ovarian malignancies,
88.5% of all serous tumours, 57.9% of all endometrioid
tumours, 62.5% of all mucinous tumours, 81.2% of all
clear cell tumours and 85.4% of other epithelial ovarian
cancer plasma samples were correctly identified (Table
5). The IVDMIA correctly predicted 91.7% of the late
stage (Stages III-IV) samples, and 69.6% of the early
Figure 2 Comparison of individual biomarker concentrations in plasma of patients with serous versus non-serous malignant ovarian
cancer. A total of 244 normal controls (Con), 223 patients with benign gynecological conditions (Ben), 130 cases of malignant serous and 92
cases of non-serous ovarian cancer were analysed. Open circles indicate the individual values of each patient measurement shown on a log
scale and horizontal lines show median concentration of each group. *: p < 0.05, compared with Con group; ^: p < 0.05 compared with Ben
group (Kruskal-Wallis test followed by Dunn’s multiple comparison test)
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(Table 5).
Discussion
The primary aims of this study were to: (i) further vali-
date the efficacy of an IVDMIA to correctly classify
ovarian cancer in symptomatic women; and (ii) to estab-
lish the utility of three different methods for assessing
incremental diagnostic performance. The performance
of the IDVMIA was compared with CA125 alone using
AUC, IDI and NRI. An independent cohort of 742
patient samples that were derived from multiple collec-
tion sites that included a substantial proportion of
women with benign gynecological conditions and bor-
derline ovarian cancer was used to establish these aims.
The diagnostic performance of the IVDMIA was shown
to be superior to that of CA125 alone as demonstrated
by comparison of AUC and by two new measures of
performance, IDI and NRI that offer incremental infor-
mation over AUC.
Each of the five biomarkers tested showed significant
elevation in malignant epithelial ovarian cancer patient
plasma compared with either normal control subjects or
subjects with confirmed benign gynecological lesions,
suggesting that each marker individually showed some
ability to discriminate malignant from non-malignant
conditions. Furthermore, only two of the five markers,
CA125 and IL8, displayed elevated concentrations in
plasma of benign patients compared with normal con-
trols indicating that CRP, SAA and IL6 should be most
effective in classifying benign lesions as non-malignant.
While all of the five biomarkers examined were signifi-
cantly elevated in plasma samples taken from patients
diagnosed with either epithelial ovarian malignancies of
serous and non-serous histotypes, only CA125 concen-
trations were significantly lower in the non-serous
group, consistent with previous studies [6]. The differen-
tial expression of CA125 between serous and non-serous
ovarian cancer histotypes suggests that additional bio-
markers such as CRP, SAA, IL6 and IL8 may comple-
ment the diagnostic efficacy of CA125, particularly for
non-serous histotypes.
Consistent with our previous study [8], we confirm
that if the multimarker model was constructed using
only the control and malignant ovarian cancer groups,
the IVDMIA delivered a significant diagnostic advantage
over the use of CA125 alone, indicating consistent per-
formance of the panel in an independent sample set.
The preferred multimarker model was then constructed
using the broader combination of normal control and
Table 3 ROC-AUC comparison of 5-marker multianalyte
test with CA125
ROC-AUC 95% CI SN at 90% SP SN at 95% SP
CA125 84.3% 80.6-87.2 62.5 62.5
5-marker panel 88.4% 85.3-91.0 77.5 69.5
Comparison by ROC-AUC analysis of 5-marker multianalyte test (CA125, CRP,
SAA, IL6 and IL8) with CA125 for the discrimination of control and benign
from patients with all stages of malignant epithelial ovarian cancer and
borderline ovarian cancer cases. Sensitivities (SN) at selected specificities (SP)
of 90% and 95% are shown.
Table 4 Statistical comparison of diagnostic efficiency
between the 5-marker multianalyte test and CA125
Statistical Comparison Estimate 95% CI p value (bootstrap)
Δ ROC AUC 4.10 1.80-6.6 < 0.001
IDI 6.60 4.70-8.60 < 0.001
NRI 8.23 6.82-9.49 < 0.001
Comparisons of diagnostic performance for discrimination of control/benign
from borderline/malignant ovarian cancer groups using AUC, IDI and NRI.
Figure 3 Association between patient group and predicted
posterior probability values. A) Scatter plots showing the
distribution of predicted posterior probability values for each patient
sample across all groups and B), the predicted posterior probability
values for each patient sample within the Control + Benign versus
Borderline + Malignant groups. Horizontal bars represent median
values for each group. For multi-group comparisons, *: p < 0.001,
compared with Con group; ^: p < 0.001 compared with Ben group
(Kruskal-Wallis test followed by Dunn’s multiple comparison test).
For two group comparisons, p < 0.0001, compared with Con + Ben
group (Mann Whitney test)
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cancer samples. When biomarker data was combined
into a multivariate classification model to generate
cross-validated posterior probability values to generate a
ROC curve as previously described [8], the resulting
AUC for the IVDMIA was shown to be significantly
greater than that observed for CA125 alone for the dis-
crimination of control/benign samples from borderline/
malignant patients. Comparison of sensitivity of the
multimarker panel with CA125 at a fixed specificity of
95% demonstrated enhanced performance of the multi-
variate index (69.5% vs 62.5%).
The multianalyte test delivered posterior probability
values across the subject groups that displayed an incre-
mental increase from benign to borderline to malignant
ovarian cancer patients. Although the borderline group
were the most difficult to accurately predict, combining
borderline and malignant ovarian cancer patients
resulted in a highly significant difference in posterior
probabilities compared with the control/benign group.
Using a posterior probability threshold of 0.5, the IVD-
MIA delivered a specificity of 92.3% and a sensitivity of
76.4%. The inclusion of patients with benign lesions and
borderline tumours into the present sample cohort
resulted in slightly lower overall AUC and sensitivity
and specificity of both the multimarker panel and
CA125 than observed in our previous biomarker trial,
however, the statistically significant improvement in
AUC and sensitivity and specificity over CA125 in this
broader independent study cohort was maintained.
Although the AUC has become the most widely used
measure of comparing performance of models for binary
outcomes, it has become apparent that with a reason-
ably efficient marker or model, relatively small changes
in AUC may not adequately describe the true clinical
incremental contribution of adding new markers or of
an alternative model [15]. Such observations have led to
the development of new indices of classification
improvement, the IDI that is based on the integral of
sensitivity and specificity over all possible thresholds
and can be used to quantify the increase in separation
of case and controls and the NRI that is based on
reclassification tables that quantify the correct move-
ment in categories [15,16]. It has been suggested that
these new measures offer incremental information over
t h eA U Ca n ds h o u l db ec o n s i d e r e di na d d i t i o nt oA U C
when assessing the differential performance of new
models [15,16]. In order to further validate the overall
diagnostic performance of the multimarker panel com-
pared with CA125 for the discrimination of borderline
and malignant ovarian cancer patients from control/
benign patients, cross validated probabilities from the
multimarker model were compared with CA125 by IDI
and NRI. Using these alternative approaches to assess
improvement in diagnostic performance also demon-
strated the significant advantage (p < 0.001) of the IVD-
MIA over CA125. In summary, this study confirms,
using three different statistical methodologies that the
five-marker multianalyte panel provides significantly bet-
ter diagnostic performance than CA125 for the discrimi-
nation of borderline and malignant ovarian cancer
plasma samples from control and benign subjects.
A variety of approaches have been proposed for
designing and testing multianalyte panels as aids for the
diagnosis of ovarian cancer. Several multimarker panels
have been shown to have considerable predictive advan-
tage over the use of CA125 alone in different patient
cohorts and settings as well as in different study designs
that include retrospective, longitudinal and prospective
studies [7,9-11,13,23]. While some marker panels are
aimed at discriminating benign from malignant adnexal
masses prior to surgery [10,11,14,24], others are being
developed as panels for the early detection of ovarian
cancer that may ultimately serve as part of a multi-step
screening process [23]. In a prospective study of women
undergoing surgery for adnexal mass, Moore et al.
reported that the combination of CA125 and HE4 deliv-
ered significantly better discrimination of benign disease
versus ovarian cancer than did CA125 alone, with a
cross-validated sensitivity of 76.4% at 95% specificity
[10]. A similar study, using this dual biomarker panel
Table 5 Proportion of samples correctly classified by the
multimarker algorithm
Correct/Total (%)
Normal 239/244 (97.9)
Benign 192/223 (86.1)
Borderline 26/53 (49.1)
Malignant 184/222 (82.9)
Malignant EOC by Stage
I II III IV UNK
Ser 10/14 11/14 74/80 11/12 9/10 115/130
(71.4) (78.6) (92.5) (91.7) (90.0) (88.5)
Endo 4/7 1/6 4/4 2/2 11/19
(57.1) (16.7) (100) (100) (57.9)
Muc 6/8 1/3 3/5 10/16
(75.0) (33.3) (60.0) (62.5)
CC 5/8 1/1 7/7 13/16
(62.5) (100) (100) (81.2)
Other 4/5 6/6 11/12 2/2 12/16 35/41
(80.0) (100) (91.7) (100) (75.0) (85.4)
Classification of samples at a threshold of 0.5 using posterior probability
values derived from an algorithm based on modelling of Control + Benign
versus Borderline + Malignant ovarian cancer patients.
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ovarian cancer in premenopausal and postmenopausal
women with pelvic mass demonstrated sensitivities and
specificities of 92.3% and 74.7% versus 76.5% and 74.8%
in the postmenopausal and premenopausal groups
respectively [25]. A more recent study assessed the clini-
cal utility of replacing CA125 with a five-marker multia-
nalyte test in the American College of Obstetricians and
Gynecologists referral guidelines for women with pelvic
mass. This study evaluated 516 women with ovarian
mass and demonstrated that substituting CA125 with
the multimarker test led to increased sensitivity (94% vs
77%) but decreased specificity (35% vs 68%) across all
patients [14].
CA125 is still the most widely used biomarker test
that shows clinical utility in the monitoring of ovarian
malignancy as well as the preoperative diagnosis of sus-
pected ovarian cancer. The present biomarker panel
described here is aimed at providing an alternative to
CA125 that will deliver higher diagnostic efficiency that
can be used as an aid in the early preoperative diagnos-
tic process. It has been recently suggested that a limita-
tion of several studies examining the efficacy of
biomarker panels for the early prediction of ovarian can-
cer is that samples are sourced predominantly from
symptomatic rather than asymptomatic women [26].
Furthermore, this study suggested that several previously
published multimarker panels that displayed apparently
better performance than CA125 failed to do so in a
study using prediagnostic samples [26]. While this is a
particularly important point of consideration if the
intended use of the biomarker panel is for screening of
pre-symptomatic women, it is less critical if the
intended use is as a diagnostic marker panel to aid
assessment of symptomatic patients, as is the case with
the current study.
The biomarkers measured in this study represent pro-
teins that are known to be expressed and released from
malignant ovarian epithelium as well as proteins that
may be induced and released from other sites as part of
an acute and/or ongoing inflammatory response or
response to injury. It is well established that the CA125
epitope is contained in MUC16, a transmembrane glyco-
protein that is expressed in endothelial ovarian cancer
cells and subsequently shed into the circulation, thereby
providing a measurable blood biomarker [27]. The acute
phase protein CRP is produced predominantly by hepa-
tocytes and its elevated concentration in the serum of
ovarian cancer patients has been shown to be indepen-
dently associated with FIGO stage and overall 5-year
survival [28]. Circulating blood concentrations and
expression of SAA, IL6 and IL8 have been shown to be
correlated with ovarian tumour stage and also with
patient survival [29-32]. While the source of circulating
SAA, IL6 and IL8 in ovarian cancer patients is not clear,
it has been demonstrated that these proteins are
expressed and secreted from ovarian cancer cells
[30,32,33]. Furthermore, there is evidence that IL6 and
IL8 in particular can exert biological actions that influ-
ence ovarian cancer cell growth and migration
[30,34,35]. Taken together, there is substantial evidence
to suggest that although several of these biomarkers are
traditionally considered to be systemic acute phase or
inflammatory markers, expression of most of these pro-
teins can occur locally in the malignant ovarian epithe-
lium where they may have biological actions on the
growth and development of these tumours.
Conclusions
The study reported here is part of a larger multi-site,
multi-national phase 2 biomarker evaluation and serves
to validate the enhanced performance of a multianalyte
panel over that of CA125 in an independent sample set
comprised of borderline and malignant epithelial ovarian
cancer patients and a control cohort made up of both
normal women as well as women diagnosed with benign
gynecological lesions. We have established a statistically
significant increase in the performance of the multimar-
ker test using the traditional and well established com-
parison of AUC as well as using two new measures of
performance of predictive models, IDI and NRI. The
current data demonstrate that the biomarker panel has
utility as an improved diagnostic aid for assessing the
likelihood of ovarian cancer in clinically presenting
symptomatic women.
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